UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives

Pharmaceutics, 2024-04, Vol.16 (4), p.557

2024

Volltextzugriff (PDF)

Design Principles Governing the Development of Theranostic Anticancer Agents and Their Nanoformulations with Photoacoustic Properties

Pharmaceutics, 2022-02, Vol.14 (2), p.362

2022

Volltextzugriff (PDF)

Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable “click” oxime bond tethers and preclinical evaluation against prostate cancer

European journal of medicinal chemistry, 2021-02, Vol.211, p.113018, Article 113018

2021

Volltextzugriff (PDF)

Construction of Peptide-Drug Conjugates for Selective Targeting of Malignant Tumor Cells

Methods in molecular biology (Clifton, N.J.), 2021, Vol.2207, p.327

2021

Volltextzugriff (PDF)

Probing the interaction of a quercetin bioconjugate with Bcl‐2 in living human cancer cells with in‐cell NMR spectroscopy

FEBS letters, 2018-10, Vol.592 (20), p.3367-3379

2018

Volltextzugriff (PDF)

Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid

Free radical biology & medicine, 2020-11, Vol.160, p.391-402

2020

Volltextzugriff (PDF)

Development of novel GnRH and Tat based luminescent probes with enhanced cellular uptake and bioimaging profile

Dalton transactions : an international journal of inorganic chemistry, 2021-07, Vol.5 (26), p.9215-9224

2021

Volltextzugriff (PDF)

Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation

Journal of biomolecular structure & dynamics, 2022-01, Vol.40 (24), p.13889-13900

2022

Volltextzugriff (PDF)

Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity

Chemistry : a European journal, 2020-08, Vol.26 (47), p.10690-10694

2020

Volltextzugriff (PDF)

Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile

European journal of medicinal chemistry, 2019-03, Vol.166, p.256-266

2019

Volltextzugriff (PDF)

Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL

Organic & biomolecular chemistry, 2017-09, Vol.15 (37), p.7956-7976

2017

Volltextzugriff (PDF)

Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2018-08, Vol.1092, p.515-523

2018

Volltextzugriff (PDF)

Development of novel GnRH and Tat48–60 based luminescent probes with enhanced cellular uptake and bioimaging profile

Dalton transactions : an international journal of inorganic chemistry, 2021-07, Vol.50 (26), p.9215-9224

2021

Volltextzugriff (PDF)

Development of novel GnRH and Tat 48–60 based luminescent probes with enhanced cellular uptake and bioimaging profile

Dalton transactions : an international journal of inorganic chemistry, 2021-07, Vol.50 (26), p.9215-9224

2021

Volltextzugriff (PDF)

Unveiling and tackling guanidinium peptide coupling reagent side reactions towards the development of peptide-drug conjugates

RSC advances, 2017, Vol.7 (80), p.50519-50526

2017

Volltextzugriff (PDF)

Cover Feature: Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity (Chem. Eur. J. 47/2020)

Chemistry : a European journal, 2020-08, Vol.26 (47), p.10646-10646

2020

Volltextzugriff (PDF)

Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xLElectronic supplementary information (ESI) available. See DOI: 10.1039/c7ob02045g

2017-09

Volltextzugriff (PDF)

Development of bioactive gemcitabine-D-Lys 6 -GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile

European journal of medicinal chemistry, 2019-03, Vol.166, p.256

2019

Volltextzugriff (PDF)

Unveiling and tackling guanidinium peptide coupling reagent side reactions towards the development of peptide-drug conjugatesElectronic supplementary information (ESI) available: Spectroscopic data, 1H-NMR, 13C-NMR and MS analysis for all new compounds. See DOI: 10.1039/c7ra06655d

2017-10

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

ThemaCytotoxicity

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(20)

Sprache

Englisch
(19)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives

Design Principles Governing the Development of Theranostic Anticancer Agents and Their Nanoformulations with Photoacoustic Properties

Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable “click” oxime bond tethers and preclinical evaluation against prostate cancer

Construction of Peptide-Drug Conjugates for Selective Targeting of Malignant Tumor Cells

Probing the interaction of a quercetin bioconjugate with Bcl‐2 in living human cancer cells with in‐cell NMR spectroscopy

Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid

Development of novel GnRH and Tat based luminescent probes with enhanced cellular uptake and bioimaging profile

Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation

Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity

Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile

Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL

Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings

Development of novel GnRH and Tat48–60 based luminescent probes with enhanced cellular uptake and bioimaging profile

Development of novel GnRH and Tat 48–60 based luminescent probes with enhanced cellular uptake and bioimaging profile

Unveiling and tackling guanidinium peptide coupling reagent side reactions towards the development of peptide-drug conjugates

Cover Feature: Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity (Chem. Eur. J. 47/2020)

Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xLElectronic supplementary information (ESI) available. See DOI: 10.1039/c7ob02045g

Development of bioactive gemcitabine-D-Lys 6 -GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile

Unveiling and tackling guanidinium peptide coupling reagent side reactions towards the development of peptide-drug conjugatesElectronic supplementary information (ESI) available: Spectroscopic data, 1H-NMR, 13C-NMR and MS analysis for all new compounds. See DOI: 10.1039/c7ra06655d

A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter‐Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine

Aktive Filter

Suchergebnisse filtern